Riskpilot← Back to searchSign inGet full accessNORSK LEGESENTER AS
ASActiveOrg 961314496Hegdehaugsveien 31, 0352 OsloGeneral medical practice activities · NACE 8621Est. 19910 employees
Revenue 2024
NOK 20K
EBITDA margin
67.4%
+133% vs 2023
Equity ratio
93.2%
Financial strength
Net profit 2024
NOK 14K
+133% vs 2023
| Revenue | NOK 20K | — |
| EBITDA | NOK 14K | +133% |
| Net profit | NOK 14K | +133% |
| Total assets | NOK 291K | +5% |
| Equity | NOK 271K | +5% |
| Employees | 0 | — |
Legal name
NORSK LEGESENTER AS
Org number
961314496
Legal form
Aksjeselskap
NACE code
8621 · General medical practice activities
Founded
18. juli 1991
Share capital
NOK 1 134 110
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Medisinsk virksomhet i videste forstand, inklusive pleie og omsorg, samt salg og utleie av medisinsk utstyr, medisinsk personell og lokaler. Selskapet kan være hel- eller deleier av andre selskaper som driver innen medisinsk virksomhet.
Address
Hegdehaugsveien 31, 0352 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 737 | 41 | 18 | 0 | 20 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 126 | −73 | −89 | 6 | 14 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 126 | −73 | −89 | 6 | 14 |
| Net financials | −0 | −0 | 0 | 0 | 0 |
| Profit before tax | 126 | −73 | −89 | 6 | 14 |
| Tax | −33 | −0 | −0 | −0 | −0 |
| Net profit | 159 | −73 | −89 | 6 | 14 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 457 | 341 | 286 | 277 | 291 |
| Equity | 414 | 341 | 252 | 258 | 271 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 43 | 0 | 34 | 20 | 20 |
| Total debt | 43 | 0 | 34 | 20 | 20 |
EBITDA margin
67.4%
This company
15.8%
Market median
+327% vs market
20202024
Equity ratio
93.2%
This company
38.2%
Market median
+144% vs market
20202024
Return on equity
5.0%
This company
18.4%
Market median
-73% vs market
20202024
Net profit margin
67.4%
This company
8.1%
Market median
+732% vs market
20202024
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20202024
Debt / equity
0.07×
This company
0.62×
Market median
+89% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ME Deputy Member | Deputy Member | 2014 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2014 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 98.21% | 98.21% | 2022 | |
| Company | 1.79% | 1.79% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Biozym Medical As
NORSK LEGESENTER AS Board members of NORSK LEGESENTER AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Marit Espeland Tholfsen | Deputy Member | 0 companies |
| Olav Espeland | Chairman | 0 companies |